Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
According to the agency, the 15-year-old company only presented efficacy claims for its branded medication and did not include any warnings or precautions for the tablets at a tradeshow.
New treatments for graft-vs.-host disease, updated dosage for HPV vaccines — and Fred Hutch announces awards for graduate students.
Patients with RA who have used b/tsDMARDs demonstrated similar risks for multiple myeloma when compared with those taking only csDMARDs.
An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...
The FDA has sent its first untitled letter of 2025, hitting Edenbridge Pharmaceuticals with a notice after assessin | The FDA ...
The Health, Hope and Hip Hop Foundation made history this February, hosting its first-ever "Hip Hope Ball: A Celebration to Ignite Change" on the final ...
More than three decades after the EPA added Fort Ord to its list of most contaminated places, the former base is still being ...
WCPO Cincinnati, OH on MSN2d
She has multiple myeloma cancer. It can’t be cured, and she blames the Army.More than three decades after the EPA added Fort Ord to its list of most contaminated places, the former base is still being ...
Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies like multiple myeloma and lymphomas, represent significant treatment ...
For what appears to be the first time, the FDA scolded a company for a promotional display that falsely claimed its ...
Multiple myeloma (MM) is a blood cancer that affects plasma cells in bone marrow. It’s a particularly insidious form of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback